36 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
28231524	6	Discovery of novel CDK8 inhibitors using multiple crystal structures in docking-based virtual screening.	West China Hospital of Sichuan University
27171036	164	Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy.	University of Nebraska Medical Center
27490956	59	Structure-Based Optimization of Potent, Selective, and Orally Bioavailable CDK8 Inhibitors Discovered by High-Throughput Screening.	Merck
27326329	102	2,8-Disubstituted-1,6-Naphthyridines and 4,6-Disubstituted-Isoquinolines with Potent, Selective Affinity for CDK8/19.	The Institute of Cancer Research
26985305	34	Development of a Potent, Specific CDK8 Kinase Inhibitor Which Phenocopies CDK8/19 Knockout Cells.	Genentech
26796641	55	Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19.	The Institute of Cancer Research
26852363	72	Discovery of potent and selective CDK8 inhibitors from an HSP90 pharmacophore.	Merck
30639897	48	Recent development of CDK inhibitors: An overview of CDK/inhibitor co-crystal structures.	The First Affiliated Hospital of Zhengzhou University
32502343	79	Discovery of MFH290: A Potent and Highly Selective Covalent Inhibitor for Cyclin-Dependent Kinase 12/13.	Harvard Medical School
27326333	54	Design and Development of a Series of Potent and Selective Type II Inhibitors of CDK8.	Genentech
30594029	42	CDK8 as a therapeutic target for cancers and recent developments in discovery of CDK8 inhibitors.	Shaoxing University
32071678	6	Discovery of 4-Piperazine Isoquinoline Derivatives as Potent and Brain-Permeable Tau Prion Inhibitors with CDK8 Activity.	University of California
30630717	2	Shape-based virtual screen for the discovery of novel CDK8 inhibitor chemotypes.	Wannan Medical College
31895562	76	Discovery of a Novel, Highly Potent, and Selective Thieno[3,2-	Takeda Pharmaceutical
31622099	44	Discovery of a Series of 5-Azaquinazolines as Orally Efficacious IRAK4 Inhibitors Targeting MyD88	Astrazeneca
31526603	379	Structure-based rational design of staurosporine-based fluorescent probe with broad-ranging kinase affinity for kinase panel application.	Takeda Pharmaceutical
29398441	111	Optimization of permeability in a series of pyrrolotriazine inhibitors of IRAK4.	Astrazeneca
30253346	46	Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor.	Chinese Academy of Sciences
29266937	36	Cyclin-Dependent Kinase 8: A New Hope in Targeted Cancer Therapy?	University of South Australia
30067358	79	Discovery of 3-Benzyl-1-( trans-4-((5-cyanopyridin-2-yl)amino)cyclohexyl)-1-arylurea Derivatives as Novel and Selective Cyclin-Dependent Kinase 12 (CDK12) Inhibitors.	Takeda Pharmaceutical
28802632	19	Discovery of potent and selective CDK8 inhibitors through FBDD approach.	Roche Innovation Center Shanghai
28956923	34	Discovery of 1-(4-(4-Amino-3-(4-(2-morpholinoethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)-3-(5-(tert-butyl)isoxazol-3-yl)urea (CHMFL-FLT3-213) as a Highly Potent Type II FLT3 Kinase Inhibitor Capable of Overcoming a Variety of FLT3 Kinase Mutants in FLT3-ITD Positive AML.	Chinese Academy of Sciences
28302507	124	Design and synthesis of selective CDK8/19 dual inhibitors: Discovery of 4,5-dihydrothieno[3',4':3,4]benzo[1,2-d]isothiazole derivatives.	Takeda Pharmaceutical
28392276	73	Studies of CDK 8/19 inhibitors: Discovery of novel and selective CDK8/19 dual inhibitors and elimination of their CYP3A4 time-dependent inhibition potential.	Takeda Pharmaceutical